Listed by the USPTO as VAJDA, KRISTIN ANN
Tech Center 1600 • Art Units: 1622 1624 1626
This examiner grants 84% of resolved cases
VAJDA, KRISTIN ANN has 1628 resolved cases in tech center 1600 and art unit 1622. The allowance rate is 83.8%, the interview lift is 11.1%, and the median time to allowance is 657 days. The large record supports a substantial view of prosecution outcomes. Allowance occurs in most resolved matters, while the interview association is comparatively limited. The median indicates a shorter timeline than many extended prosecution records.
The main companies are Pfizer Inc., Samsung Display Co., Ltd., and The University of British Columbia. The leading firms are NIXON & VANDERHYE, PC, ALSTON & BIRD LLP, and ARENTFOX SCHIFF LLP. Applicants may prioritize clear claim drafting and efficient issue resolution, using interviews selectively rather than relying on them as the primary source of improvement.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18322819 | DONOR-ACCEPTOR-DONOR TYPE MATERIALS FOR OPTOELECTRONIC APPLICATIONS | Non-Final OA | The Regents of the University of Michigan |
| 18702299 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | Non-Final OA | Samsung Display Co., Ltd. |
| 17282319 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | Final Rejection | The University of British Columbia |
| 18287646 | THERAPY FOR ALCOHOL-RELATED LIVER DISEASE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18934691 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | Non-Final OA | THE TRUSTEES OF PRINCETON UNIVERSITY |
| 18687448 | COMBINATIONS OF CANNABIS AND PLANT-DERIVED COMPOUNDS AS ANTI-CELL PROLIFERATION-RELATED DISEASE AGENTS | Non-Final OA | ARIEL SCIENTIFIC INNOVATIONS LTD. |
| 18518816 | AGENT FOR PREVENTING OR AMELIORATING PRURITUS | Non-Final OA | KAO CORPORATION |
| 18789272 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Non-Final OA | Pfizer Inc. |
| 19024658 | METHOD OF TREATING CONDITIONS RELATED TO THE PGI2 RECEPTOR | Non-Final OA | Arena Pharmaceuticals, Inc. |
| 18701027 | IMPROVED SELECTIVE JAK2 INHIBITORS AND METHODS OF USE | Non-Final OA | Yale University |
| 18263772 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS | Non-Final OA | LG CHEM, LTD. |
| 18799659 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18568615 | COMPOSITIONS AND METHODS FOR TREATING NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS | Non-Final OA | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy83.8% of resolved applications examined by Kristin Ann Vajda were allowed (1,628 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.
This examiner's interview lift is +11.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kristin Ann Vajda took 657 days on average from filing to allowance.
Kristin Ann Vajda examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
